Stephan Ruhrmann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5277935/publications.pdf

Version: 2024-02-01

217 papers

14,035 citations

59 h-index 24258 110 g-index

257 all docs

257 docs citations

times ranked

257

11600 citing authors

#	Article	IF	Citations
1	The non-specific nature of mental health and structural brain outcomes following childhood trauma. Psychological Medicine, 2023, 53, 1005-1014.	4.5	6
2	Relationship between jumping to conclusions and clinical outcomes in people at clinical high-risk for psychosis. Psychological Medicine, 2022, 52, 1569-1577.	4.5	11
3	Impact of Comorbid Affective Disorders on Longitudinal Clinical Outcomes in Individuals at Ultra-high Risk for Psychosis. Schizophrenia Bulletin, 2022, 48, 100-110.	4.3	9
4	The clinical relevance of formal thought disorder in the early stages of psychosis: results from the PRONIA study. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 403-413.	3.2	10
5	Verbal memory performance predicts remission and functional outcome in people at clinical high-risk for psychosis. Schizophrenia Research: Cognition, 2022, 28, 100222.	1.3	10
6	Relationships between global functioning and neuropsychological predictors in subjects at high risk of psychosis or with a recent onset of depression. World Journal of Biological Psychiatry, 2022, 23, 573-581.	2.6	3
7	Impact of smoking behavior on cognitive functioning in persons at risk for psychosis and healthy controls: A longitudinal study – CORRIGENDUM. European Psychiatry, 2022, 65, e17.	0.2	0
8	Using combined environmental–clinical classification models to predict role functioning outcome in clinical high-risk states for psychosis and recent-onset depression. British Journal of Psychiatry, 2022, 220, 229-245.	2.8	1
9	Pattern of predictive features of continued cannabis use in patients with recent-onset psychosis and clinical high-risk for psychosis. NPJ Schizophrenia, 2022, 8, 19.	3.6	1
10	Neurobiologically Based Stratification of Recent-Onset Depression and Psychosis: Identification of Two Distinct Transdiagnostic Phenotypes. Biological Psychiatry, 2022, 92, 552-562.	1.3	15
11	Clinical, Brain, and Multilevel Clustering in Early Psychosis and Affective Stages. JAMA Psychiatry, 2022, 79, 677.	11.0	6
12	Clinical, cognitive and neuroanatomical associations of serum NMDAR autoantibodies in people at clinical high risk for psychosis. Molecular Psychiatry, 2021, 26, 2590-2604.	7.9	16
13	The Psychopathology and Neuroanatomical Markers of Depression in Early Psychosis. Schizophrenia Bulletin, 2021, 47, 249-258.	4.3	13
14	Dysregulated Lipid Metabolism Precedes Onset of Psychosis. Biological Psychiatry, 2021, 89, 288-297.	1.3	42
15	Development of Proteomic Prediction Models for Transition to Psychotic Disorder in the Clinical High-Risk State and Psychotic Experiences in Adolescence. JAMA Psychiatry, 2021, 78, 77.	11.0	57
16	Genome-wide association study of pediatric obsessive-compulsive traits: shared genetic risk between traits and disorder. Translational Psychiatry, 2021, 11, 91.	4.8	23
17	Heterogeneity and Classification of Recent Onset Psychosis and Depression: A Multimodal Machine Learning Approach. Schizophrenia Bulletin, 2021, 47, 1130-1140.	4.3	23
18	Multimodal Machine Learning Workflows for Prediction of Psychosis in Patients With Clinical High-Risk Syndromes and Recent-Onset Depression. JAMA Psychiatry, 2021, 78, 195.	11.0	125

#	Article	IF	CITATIONS
19	Obsessive-Compulsive Symptoms and Other Symptoms of the At-risk Mental State for Psychosis: A Network Perspective. Schizophrenia Bulletin, 2021, 47, 1018-1028.	4.3	10
20	Association between age of cannabis initiation and gray matter covariance networks in recent onset psychosis. Neuropsychopharmacology, 2021, 46, 1484-1493.	5.4	14
21	Cognitive subtypes in recent onset psychosis: distinct neurobiological fingerprints?. Neuropsychopharmacology, 2021, 46, 1475-1483.	5.4	15
22	Multimodal prognosis of negative symptom severity in individuals at increased risk of developing psychosis. Translational Psychiatry, 2021, 11, 312.	4.8	7
23	Is there a diagnosis-specific influence of childhood trauma on later educational attainment? A machine learning analysis in a large help-seeking sample. Journal of Psychiatric Research, 2021, 138, 591-597.	3.1	1
24	Towards clinical application of prediction models for transition to psychosis: A systematic review and external validation study in the PRONIA sample. Neuroscience and Biobehavioral Reviews, 2021, 125, 478-492.	6.1	31
25	Toward Generalizable and Transdiagnostic Tools for Psychosis Prediction: An Independent Validation and Improvement of the NAPLS-2 Risk Calculator in the Multisite PRONIA Cohort. Biological Psychiatry, 2021, 90, 632-642.	1.3	32
26	Novel Gyrification Networks Reveal Links with Psychiatric Risk Factors in Early Illness. Cerebral Cortex, 2021, , .	2.9	2
27	Impact of Smoking Behavior on Cognitive Functioning in Persons at Risk for Psychosis and Healthy Controls: A Longitudinal Study. European Psychiatry, 2021, 64, 1-20.	0.2	2
28	Association between tobacco use and symptomatology in individuals at ultra-high risk to develop a psychosis: A longitudinal study. Schizophrenia Research, 2021, 236, 48-53.	2.0	6
29	Attitudes towards Risk Prediction in a Help Seeking Population of Early Detection Centers for Mental Disorders—A Qualitative Approach. International Journal of Environmental Research and Public Health, 2021, 18, 1036.	2.6	3
30	Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings. Molecular Psychiatry, 2021, 26, 4529-4543.	7.9	23
31	Detailed clinical phenotyping and generalisability in prognostic models of functioning in at-risk populations. British Journal of Psychiatry, 2021, , 1-4.	2.8	0
32	A randomized Phase <scp>II</scp> trial evaluating efficacy, safety, and tolerability of oral <scp>BI</scp> 409306 in attenuated psychosis syndrome: Design and rationale. Microbial Biotechnology, 2021, 15, 1315-1325.	1.7	7
33	Age effects on basic symptoms in the community: A route to gain new insight into the neurodevelopment of psychosis?. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 311-324.	3.2	19
34	Peculiarities of health literacy in people with mental disorders: A cross-sectional study. International Journal of Social Psychiatry, 2020, 66, 10-22.	3.1	15
35	Sex differences in symptomatology of psychosis-risk patients and in prediction of psychosis. Archives of Women's Mental Health, 2020, 23, 339-349.	2.6	9
36	Association of Adverse Outcomes With Emotion Processing and Its Neural Substrate in Individuals at Clinical High Risk for Psychosis. JAMA Psychiatry, 2020, 77, 190.	11.0	23

#	Article	IF	Citations
37	S94. PREDICTION OF CANNABIS RELAPSE IN CLINICAL HIGH-RISK INDIVIDUALS AND RECENT ONSET PSYCHOSIS - PRELIMINARY RESULTS FROM THE PRONIA STUDY. Schizophrenia Bulletin, 2020, 46, S69-S70.	4.3	0
38	Pre-training inter-rater reliability of clinical instruments in an international psychosis research project. Schizophrenia Research, 2020, 230, 104-107.	2.0	6
39	Traces of Trauma: A Multivariate Pattern Analysis of Childhood Trauma, Brain Structure, and Clinical Phenotypes. Biological Psychiatry, 2020, 88, 829-842.	1.3	35
40	Atypical processing of uncertainty in individuals at risk for psychosis. NeuroImage: Clinical, 2020, 26, 102239.	2.7	37
41	Sex differences in cognitive functioning of patients at-risk for psychosis and healthy controls: Results from the European Gene–Environment Interactions study. European Psychiatry, 2020, 63, e25.	0.2	14
42	Emotion Recognition and Adverse Childhood Experiences in Individuals at Clinical High Risk of Psychosis. Schizophrenia Bulletin, 2020, 46, 823-833.	4.3	14
43	Validation of the Bullying Scale for Adults - Results of the PRONIA-study. Journal of Psychiatric Research, 2020, 129, 88-97.	3.1	8
44	General psychopathology links burden of recent life events and psychotic symptoms in a network approach. NPJ Schizophrenia, 2020, 6, 40.	3.6	28
45	Basic Symptoms Are Associated With Age in Patients With a Clinical High-Risk State for Psychosis: Results From the PRONIA Study. Frontiers in Psychiatry, 2020, 11, 552175.	2.6	5
46	Childhood adversity predicts persistence of suicidal thoughts differently in females and males at clinical highâ€risk patients of psychosis. Results of the EPOS project. Microbial Biotechnology, 2019, 13, 935-942.	1.7	14
47	Resilience as a multimodal dynamic process. Microbial Biotechnology, 2019, 13, 725-732.	1.7	135
48	The interrelationship between schizotypy, clinical high risk for psychosis and related symptoms: Cognitive disturbances matter. Schizophrenia Research, 2019, 210, 188-196.	2.0	27
49	Health literacy in clinicalâ€highâ€risk individuals for psychosis: A systematic mixedâ€methods review. Microbial Biotechnology, 2019, 13, 1293-1309.	1.7	5
50	Individualized Prediction of Transition to Psychosis in 1,676 Individuals at Clinical High Risk: Development and Validation of a Multivariable Prediction Model Based on Individual Patient Data Meta-Analysis. Frontiers in Psychiatry, 2019, 10, 345.	2.6	29
51	Gender differences of patients at-risk for psychosis regarding symptomatology, drug use, comorbidity and functioning $\hat{a} \in \mathbb{C}$ Results from the EU-GEI study. European Psychiatry, 2019, 59, 52-59.	0.2	19
52	Multimodal prevention of first psychotic episode through Nâ€acetylâ€∢scp>l⟨/scp>â€eysteine and integrated preventive psychological intervention in individuals clinically at high risk for psychosis: Protocol of a randomized, placeboâ€controlled, parallelâ€group trial. Microbial Biotechnology, 2019, 13, 1404-1415.	1.7	14
53	O6.5. INVESTIGATING VARIABLES FROM THE NAPLS RISK CALCULATOR FOR PSYCHOSIS IN THE EU-GEI HIGH RISK STUDY. Schizophrenia Bulletin, 2019, 45, S177-S178.	4.3	0
54	Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders. Cell, 2019, 179, 1469-1482.e11.	28.9	935

#	Article	IF	CITATIONS
55	Sex differences in the genetic architecture of obsessive–compulsive disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2019, 180, 351-364.	1.7	41
56	Antisaccade and prosaccade eye movements in individuals clinically at risk for psychosis: comparison with first-episode schizophrenia and prediction of conversion. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 921-930.	3.2	18
57	Expressed emotion as a predictor of the first psychotic episode â€" Results of the European prediction of psychosis study. Schizophrenia Research, 2018, 199, 346-352.	2.0	17
58	Course of clinical high-risk states for psychosis beyond conversion. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 39-48.	3.2	59
59	Child Maltreatment and Clinical Outcome in Individuals at Ultra-High Risk for Psychosis in the EU-GEI High Risk Study. Schizophrenia Bulletin, 2018, 44, 584-592.	4.3	38
60	Prevalence and clinical relevance of interview-assessed psychosis-risk symptoms in the young adult community. Psychological Medicine, 2018, 48, 1167-1178.	4.5	45
61	Revealing the complex genetic architecture of obsessive–compulsive disorder using meta-analysis. Molecular Psychiatry, 2018, 23, 1181-1188.	7.9	400
62	T239. SINGLE-SUBJECT PREDICTION OF FUNCTIONAL OUTCOMES IN CLINICAL HIGH RISK SUBJECTS USING CLINICAL DATA. Schizophrenia Bulletin, 2018, 44, S209-S210.	4.3	0
63	Prediction Models of Functional Outcomes for Individuals in the Clinical High-Risk State for Psychosis or With Recent-Onset Depression. JAMA Psychiatry, 2018, 75, 1156.	11.0	251
64	S13. DO PATIENTS WITH RECENT-ONSET DEPRESSION DIFFER CLINICALLY AND NEUROBIOLOGICALLY FROM DEPRESSED PATIENTS WITH A CLINICAL HIGH-RISK STATE FOR PSYCHOSIS?. Schizophrenia Bulletin, 2018, 44, S328-S329.	4.3	0
65	Integrating evolutionary and regulatory information with a multispecies approach implicates genes and pathways in obsessive-compulsive disorder. Nature Communications, 2017, 8, 774.	12.8	52
66	Intervention in Clinical High Risk States - Current Status and Future Perspectives. European Psychiatry, 2017, 41, S27-S28.	0.2	0
67	Clinical High Risk Symptoms and Criteria in the Community: Prevalence, Clinical Significance and Risk Factors for Their Occurrence. European Psychiatry, 2017, 41, S226-S226.	0.2	1
68	868. Early Intervention in Attenuated Psychosis Syndrome: A Phase II Study Evaluating Efficacy, Safety, and Tolerability of Oral BI 409306. Biological Psychiatry, 2017, 81, S351.	1.3	2
69	Basic Symptoms in the Community and their Association with Age. European Psychiatry, 2017, 41, S84-S85.	0.2	1
70	Revisiting the Basic Symptom Concept: Toward Translating Risk Symptoms for Psychosis into Neurobiological Targets. Frontiers in Psychiatry, 2016, 7, 9.	2.6	62
71	Development of a stage-dependent prognostic model to predict psychosis in ultra-high-risk patients seeking treatment for co-morbid psychiatric disorders. Psychological Medicine, 2016, 46, 1839-1851.	4.5	12
72	Authors' reply. British Journal of Psychiatry, 2016, 208, 197-198.	2.8	0

#	Article	IF	Citations
73	Restricted attention to social cues in schizophrenia patients. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 649-661.	3.2	26
74	Psychosis-predictive value of self-reported schizotypy in a clinical high-risk sample Journal of Abnormal Psychology, 2016, 125, 923-932.	1.9	59
75	Depression predicts persistence of paranoia in clinical high-risk patients to psychosis: results of the EPOS project. Social Psychiatry and Psychiatric Epidemiology, 2016, 51, 247-257.	3.1	20
76	Predictors for symptom re-exacerbation after targeted stepwise drug discontinuation in first-episode schizophrenia. Schizophrenia Research, 2016, 170, 168-176.	2.0	34
77	EPA guidance on the early intervention in clinical high risk states of psychoses. European Psychiatry, 2015, 30, 388-404.	0.2	390
78	Neurocognitive functioning in parents of schizophrenia patients: Attentional and executive performance vary with genetic loading. Psychiatry Research, 2015, 230, 885-891.	3.3	12
79	Cross-Disorder Genome-Wide Analyses Suggest a Complex Genetic Relationship Between Tourette's Syndrome and OCD. American Journal of Psychiatry, 2015, 172, 82-93.	7.2	117
80	Causal Connection Between Depression and Paranoia. European Psychiatry, 2015, 30, 113.	0.2	0
81	TTe Predictive Power of the Wisconsin Scales of Schizophrenia Proneness in Patients of an Early Detection Service. European Psychiatry, 2015, 30, 922.	0.2	0
82	EPA guidance on the early detection of clinical high risk states of psychoses. European Psychiatry, 2015, 30, 405-416.	0.2	318
83	Personality dimensions in persons symptomatically at risk of psychosis: pronounced but lacking a characteristic profile. Microbial Biotechnology, 2015, 9, 242-247.	1.7	8
84	Duration of unspecific prodromal and clinical high risk states, and early help-seeking in first-admission psychosis patients. Social Psychiatry and Psychiatric Epidemiology, 2015, 50, 1831-1841.	3.1	56
85	Disorder, not just state of risk: Meta-analysis of functioning and quality of life in people at high risk of psychosis. British Journal of Psychiatry, 2015, 207, 198-206.	2.8	226
86	Forecasting Psychosis by Event-Related Potentialsâ€"Systematic Review and Specific Meta-Analysis. Biological Psychiatry, 2015, 77, 951-958.	1.3	102
87	Self-Reported Psychotic-Like Experiences Are a Poor Estimate of Clinician-Rated Attenuated and Frank Delusions and Hallucinations. Psychopathology, 2014, 47, 194-201.	1.5	65
88	Identifying Gene-Environment Interactions in Schizophrenia: Contemporary Challenges for Integrated, Large-scale Investigations. Schizophrenia Bulletin, 2014, 40, 729-736.	4.3	229
89	Short-term functional outcome and premorbid adjustment in clinical high-risk patients. Results of the EPOS project. European Psychiatry, 2014, 29, 371-380.	0.2	28
90	Can quantitative EEG measures predict clinical outcome in subjects at Clinical High Risk for psychosis? A prospective multicenter study. Schizophrenia Research, 2014, 153, 42-47.	2.0	48

#	Article	IF	Citations
91	Pathways to care in subjects at high risk for psychotic disorders — A European perspective. Schizophrenia Research, 2014, 152, 400-407.	2.0	31
92	Psychosis Prediction: Stratification of Risk Estimation With Information-Processing and Premorbid Functioning Variables. Schizophrenia Bulletin, 2014, 40, 1482-1490.	4.3	91
93	5-HT3 receptor influences the washing phenotype and visual organization in obsessive-compulsive disorder supporting 5-HT3 receptor antagonists as novel treatment option. European Neuropsychopharmacology, 2014, 24, 86-94.	0.7	23
94	Prediction and prevention of psychosis: current progress and future tasks. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 9-16.	3.2	21
95	Copy Number Variation in Obsessive-Compulsive Disorder and Tourette Syndrome: A Cross-Disorder Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2014, 53, 910-919.	0.5	111
96	A Stratified Model for Psychosis Prediction in Clinical Practice. Schizophrenia Bulletin, 2014, 40, 1533-1542.	4.3	59
97	Prevalence and Clinical Significance of DSM-5–Attenuated Psychosis Syndrome in Adolescents and Young Adults in the General Population: The Bern Epidemiological At-Risk (BEAR) Study. Schizophrenia Bulletin, 2014, 40, 1499-1508.	4.3	79
98	Improving the clinical prediction of psychosis by combining ultra-high risk criteria and cognitive basic symptoms. Schizophrenia Research, 2014, 154, 100-106.	2.0	115
99	PREVENTIVE PSYCHOTHERAPY. Schizophrenia Research, 2014, 153, S42-S43.	2.0	1
100	Psychosocial outcome in patients at clinical high risk of psychosis: a prospective follow-up. Social Psychiatry and Psychiatric Epidemiology, 2013, 48, 303-311.	3.1	31
101	Morphometry of structural disconnectivity indicators in subjects at risk and in age-matched patients with schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 15-24.	3.2	26
102	Physical illnesses, developmental risk factors and psychiatric diagnoses among subjects at risk of psychosis. European Psychiatry, 2013, 28, 135-140.	0.2	3
103	Prediction of psychosis in clinical high-risk patients by the Schizotypal Personality Questionnaire. Results of the EPOS project. European Psychiatry, 2013, 28, 469-475.	0.2	41
104	The Psychosis High-Risk State. JAMA Psychiatry, 2013, 70, 107.	11.0	1,222
105	The Strauss and Carpenter Prognostic Scale in subjects clinically at high risk of psychosis. Acta Psychiatrica Scandinavica, 2013, 127, 53-61.	4.5	23
106	Genome-wide association study of obsessive-compulsive disorder. Molecular Psychiatry, 2013, 18, 788-798.	7.9	312
107	The functional coding variant Asn107lle of the neuropeptide S receptor gene (NPSR1) influences age at onset of obsessive–compulsive disorder. International Journal of Neuropsychopharmacology, 2013, 16, 1951-1958.	2.1	7
108	Partitioning the Heritability of Tourette Syndrome and Obsessive Compulsive Disorder Reveals Differences in Genetic Architecture. PLoS Genetics, 2013, 9, e1003864.	3.5	241

#	Article	IF	Citations
109	â€~A Rose Is a Rose Is a Rose', but At-Risk Criteria Differ. Psychopathology, 2013, 46, 75-87.	1.5	54
110	Characterization of SLITRK1 Variation in Obsessive-Compulsive Disorder. PLoS ONE, 2013, 8, e70376.	2.5	47
111	Basic Disturbances of Information Processing in Psychosis Prediction. Frontiers in Psychiatry, 2013, 4, 93.	2.6	7
112	Basic Symptoms and the Prediction of First-Episode Psychosis. Current Pharmaceutical Design, 2012, 18, 351-357.	1.9	152
113	Neurophysiological Correlates of Impaired Facial Affect Recognition in Individuals at Risk for Schizophrenia. Schizophrenia Bulletin, 2012, 38, 1021-1029.	4.3	60
114	Rationale and First Results of Developing At-Risk (Prodromal) Criteria for Bipolar Disorder. Current Pharmaceutical Design, 2012, 18, 358-375.	1.9	70
115	Antisaccade performance in patients with obsessive–compulsive disorder and unaffected relatives: further evidence for impaired response inhibition as a candidate endophenotype. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 625-634.	3.2	45
116	Perceived negative attitude of others predicts transition to psychosis in patients at risk of psychosis. European Psychiatry, 2012, 27, 264-266.	0.2	11
117	Pharmacological Prevention and Treatment in Clinical At-Risk States for Psychosis. Current Pharmaceutical Design, 2012, 18, 550-557.	1.9	20
118	Whither the Attenuated Psychosis Syndrome?. Schizophrenia Bulletin, 2012, 38, 1130-1134.	4.3	85
119	Preventing progression to first-episode psychosis in early initial prodromal states. British Journal of Psychiatry, 2012, 200, 22-29.	2.8	196
120	Poster #202 COMPARING THE PRODROME OF SCHIZOPHRENIA-SPECTRUM PSYCHOSES AND BIPOLAR DISORDERS WITH AND WITHOUT PSYCHOTIC FEATURES. Schizophrenia Research, 2012, 136, S163-S164.	2.0	0
121	Poster #70 COPING IN INDIVIDUALS AT CLINICAL HIGH RISK FOR PSYCHOSIS, SCHIZOPHRENIA PATIENTS AND HEALTHY CONTROL SUBJECTS. Schizophrenia Research, 2012, 136, S210-S211.	2.0	0
122	Poster #191 THE STRAUSS AND CARPENTER PROGNOSTIC SCALE IN SUBJECTS CLINICALLY AT HIGH RISK OF PSYCHOSIS. Schizophrenia Research, 2012, 136, S254.	2.0	0
123	Axis I diagnoses and transition to psychosis in clinical high-risk patients EPOS project: Prospective follow-up of 245 clinical high-risk outpatients in four countries. Schizophrenia Research, 2012, 138, 192-197.	2.0	94
124	Comparing the prodrome of schizophrenia-spectrum psychoses and affective disorders with and without psychotic features. Schizophrenia Research, 2012, 138, 218-222.	2.0	16
125	Chances and risks of predicting psychosis. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 85-90.	3.2	18
126	Cannabis use and age at onset of symptoms in subjects at clinical high risk for psychosis. Acta Psychiatrica Scandinavica, 2012, 125, 45-53.	4.5	82

#	Article	IF	Citations
127	Personality disorders and accentuations in atâ€risk persons with and without conversion to firstâ€episode psychosis. Microbial Biotechnology, 2012, 6, 389-398.	1.7	41
128	A promoter variant of SHANK1 affects auditory working memory in schizophrenia patients and in subjects clinically at risk for psychosis. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 117-124.	3.2	47
129	The Near Babylonian Speech Confusion in Early Detection of Psychosis. Schizophrenia Bulletin, 2011, 37, 653-655.	4.3	68
130	Neuropsychological Profiles in Different At-Risk States of Psychosis: Executive Control Impairment in the Early—and Additional Memory Dysfunction in the Late—Prodromal State. Schizophrenia Bulletin, 2011, 37, 861-873.	4.3	124
131	Subjective quality of life and its changes in patients at-risk for psychosis results of the EPOS study. European Psychiatry, 2011, 26, 2039-2039.	0.2	0
132	Course of psychopathology in the at-risk mental state - outcomes beyond transition to psychosis. European Psychiatry, 2011, 26, 2037-2037.	0.2	0
133	Prediction of Psychosis by Mismatch Negativity. Biological Psychiatry, 2011, 69, 959-966.	1.3	273
134	Prediction and prevention of schizophrenia: what has been achieved and where to go next?. World Psychiatry, 2011, 10, 165-174.	10.4	101
135	Prediction and Early Detection of First-Episode Psychosis. , 2011, , 207-267.		3
136	Prevention and Early Intervention in At-Risk States for Developing Psychosis., 2011,, 81-92.		0
137	Disability in people clinically at high risk of psychosis. British Journal of Psychiatry, 2010, 197, 278-284.	2.8	113
138	DAOA/G72 predicts the progression of prodromal syndromes to first episode psychosis. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 209-215.	3.2	33
139	Intervention in at-risk states for developing psychosis. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 90-94.	3.2	17
140	Search for copy number variants in chromosomes $15q11-q13$ and $22q11.2$ in obsessive compulsive disorder. BMC Medical Genetics, 2010, 11, 100.	2.1	14
141	Perceived parental rearing in subjects with obsessive–compulsive disorder and their siblings. Acta Psychiatrica Scandinavica, 2010, 121, 280-288.	4.5	33
142	The EPOS prediction model improves ability to predict transition to first episode psychosis in individuals at high risk. Evidence-Based Mental Health, 2010, 13, 77-77.	4.5	0
143	Basic Symptoms and Ultrahigh Risk Criteria: Symptom Development in the Initial Prodromal State. Schizophrenia Bulletin, 2010, 36, 182-191.	4.3	186
144	Prediction of Psychosis in Adolescents and Young Adults at High Risk. Archives of General Psychiatry, 2010, 67, 241.	12.3	575

#	Article	IF	CITATIONS
145	P03-118 - Perceived Negative Attitude Associates with Psychotic Experiences. European Psychiatry, 2010, 25, .	0.2	0
146	The interaction of working memory and emotion in persons clinically at risk for psychosis: An fMRI pilot study. Schizophrenia Research, 2010, 120, 167-176.	2.0	30
147	PREDICTION OF PSYCHOSIS BY MISMATCH NEGATIVITY. Schizophrenia Research, 2010, 117, 244.	2.0	0
148	MISMATCH NEGATIVITY IS REDUCED IN SCHIZOPHRENIA PATIENTS WITH DEFICIT SYNDROME. Schizophrenia Research, 2010, 117, 360-361.	2.0	1
149	BASIC SYMPTOM AND ULTRA-HIGH RISK CRITERIA IN THE PREDICTION OF FIRST-EPISODE PSYCHOSIS. Schizophrenia Research, 2010, 117, 422.	2.0	0
150	THE ROLE OF PERSONALITY DISORDER AND ACCENTUATION IN THE CONVERSION TO PSYCHOSIS. Schizophrenia Research, 2010, 117, 422-423.	2.0	2
151	Probably at-risk, but certainly ill $\hat{a}\in$ " Advocating the introduction of a psychosis spectrum disorder in DSM-V. Schizophrenia Research, 2010, 120, 23-37.	2.0	138
152	Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. British Journal of Psychiatry, 2009, 194, 371-372.	2.8	157
153	Gray matter abnormalities in subjects at ultra-high risk for schizophrenia and first-episode schizophrenic patients compared to healthy controls. Psychiatry Research - Neuroimaging, 2009, 173, 163-169.	1.8	127
154	Antisaccade performance is related to genetic loading for schizophrenia. Journal of Psychiatric Research, 2009, 43, 291-297.	3.1	15
155	Early onset of obsessive-compulsive disorder and associated comorbidity. Depression and Anxiety, 2009, 26, 1012-1017.	4.1	41
156	Binocular depth inversion as a paradigm of reduced visual information processing in prodromal state, antipsychotic-naÃ-ve and treated schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2009, 259, 195-202.	3.2	80
157	Early detection of psychosis – Establishing a service for persons at risk. European Psychiatry, 2009, 24, 1-10.	0.2	43
158	Perceived negative attitude of others as an early sign of psychosis. European Psychiatry, 2009, 24, 233-238.	0.2	13
159	Intervention in the at-risk state to prevent transition to psychosis. Current Opinion in Psychiatry, 2009, 22, 177-183.	6.3	24
160	Intervention in Individuals at Ultra-High Risk for Psychosis. Journal of Clinical Psychiatry, 2009, 70, 1206-1212.	2.2	258
161	Kraepelin and psychotic prodromal conditions. European Archives of Psychiatry and Clinical Neuroscience, 2008, 258, 74-84.	3.2	45
162	Reduced subjective quality of life in persons at risk for psychosis. Acta Psychiatrica Scandinavica, 2008, 117, 357-368.	4.5	68

#	Article	IF	CITATIONS
163	Harm avoidance in subjects with obsessive-compulsive disorder and their families. Journal of Affective Disorders, 2008, 107, 265-269.	4.1	58
164	PHARMACOLOGICAL INTERVENTION IN THE PRODROMAL STATE OF PSYCHOSIS. Schizophrenia Research, 2008, 102, 47-48.	2.0	0
165	Sensory Gating in Schizophrenia: P50 and N100 Gating in Antipsychotic-Free Subjects at Risk, First-Episode, and Chronic Patients. Biological Psychiatry, 2008, 64, 376-384.	1.3	212
166	Auditory P300 in individuals clinically at risk for psychosis. International Journal of Psychophysiology, 2008, 70, 192-205.	1.0	83
167	P.3.f.001 Does anandamide elevation in cerebrospinal fluid protect against transition into frank psychosis?. European Neuropsychopharmacology, 2008, 18, S474.	0.7	0
168	Increased neural response related to neutral faces in individuals at risk for psychosis. NeuroImage, 2008, 40, 289-297.	4.2	131
169	Specific neurocognitive deficits are related to inferred genetic risk in unaffected parents of schizophrenic patients. European Psychiatry, 2008, 23, S28.	0.2	0
170	Subjective quality of life and its changes in patients at risk of psychosis. European Psychiatry, 2008, 23, S68.	0.2	0
171	Transition to psychosis: Neuropsychological test results of the epos study. European Psychiatry, 2008, 23, S68-S69.	0.2	0
172	Antisaccade deficits in subjects either genetically or clinically at risk for schizophrenia. European Psychiatry, 2008, 23, S69.	0.2	0
173	Obsessive-Compulsive Disorder and Posttraumatic Stress Disorder. Psychopathology, 2008, 41, 129-134.	1.5	34
174	Interrelated neuropsychological and anatomical evidence of hippocampal pathology in the at-risk mental state. Psychological Medicine, 2008, 38, 843-851.	4.5	71
175	Relationship between subjective and objective cognitive function in the early and late prodrome. British Journal of Psychiatry, 2007, 191, s43-s51.	2.8	40
176	Basic symptoms in early psychotic and depressive disorders. British Journal of Psychiatry, 2007, 191, s31-s37.	2.8	73
177	Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. British Journal of Psychiatry, 2007, 191, s88-s95.	2.8	122
178	Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 1012-1022.	4.8	23
179	The initial prodrome of schizophrenia: different duration, different underlying deficits?. Comprehensive Psychiatry, 2007, 48, 479-488.	3.1	34
180	EPOS - sample characteristics, transition rates and psychopathological predictors. European Psychiatry, 2007, 22, S64.	0.2	0

#	Article	IF	Citations
181	Neural correlates of working memory dysfunction in first-episode schizophrenia patients: An fMRI multi-center study. Schizophrenia Research, 2007, 89, 198-210.	2.0	148
182	Neurocognitive indicators for a conversion to psychosis: Comparison of patients in a potentially initial prodromal state who did or did not convert to a psychosis. Schizophrenia Research, 2007, 92, 116-125.	2.0	175
183	Orienting of attention in unmedicated patients with schizophrenia, prodromal subjects and healthy relatives. Schizophrenia Research, 2007, 97, 35-42.	2.0	28
184	Randomized controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. Microbial Biotechnology, 2007, 1, 71-78.	1.7	54
185	Impulsiveness in obsessive?compulsive disorder: results from a family study. Acta Psychiatrica Scandinavica, 2007, 115, 41-47.	4.5	116
186	CSF Metabolic and Proteomic Profiles in Patients Prodromal for Psychosis. PLoS ONE, 2007, 2, e756.	2.5	93
187	0127 LOCUS OF CONTROL IN PERSONS CLINICALLY AT RISK FOR PSYCHOSIS. Schizophrenia Research, 2006, 86, S85.	2.0	0
188	0372 THE INTERACTION OF NEGATIVE EMOTION AND WORKING MEMORY IN EARLY PSYCHOSIS. Schizophrenia Research, 2006, 86, S109.	2.0	0
189	Alexithymia in Obsessive-Compulsive Disorder – Results from a Family Study. Psychotherapy and Psychosomatics, 2006, 75, 312-318.	8.8	48
190	No Human Tryptophan Hydroxylase-2 Gene R441H Mutation in a Large Cohort of Psychiatric Patients and Control Subjects. Biological Psychiatry, 2006, 60, 202-203.	1.3	49
191	Familiality of Obsessive-Compulsive Disorder in Nonclinical and Clinical Subjects. American Journal of Psychiatry, 2006, 163, 1986-1992.	7.2	83
192	Neurocognitive Functioning in Subjects at Risk for a First Episode of Psychosis Compared with First-and Multiple-episode Schizophrenia. Journal of Clinical and Experimental Neuropsychology, 2006, 28, 1388-1407.	1.3	129
193	Familiality of Obsessive-Compulsive Disorder in Nonclinical and Clinical Subjects. American Journal of Psychiatry, 2006, 163, 1986.	7.2	30
194	The German Research Network on Schizophrenia-impact on the management of schizophrenia. Dialogues in Clinical Neuroscience, 2006, 8, 115-121.	3.7	14
195	Support for the association between the rare functional variant I425V of the serotonin transporter gene and susceptibility to obsessive compulsive disorder. Molecular Psychiatry, 2005, 10, 1059-1061.	7.9	46
196	Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry, 2005, 187, s45-s48.	2.8	57
197	Pharmacological intervention in the initial prodromal phase of psychosis. European Psychiatry, 2005, 20, 1-6.	0.2	53
198	Impaired mismatch negativity generation in prodromal subjects and patients with schizophrenia. Schizophrenia Research, 2005, 73, 297-310.	2.0	144

#	Article	IF	CITATIONS
199	Subjective quality of life in subjects at risk for a first episode of psychosis: A comparison with first episode schizophrenia patients and healthy controls. Schizophrenia Research, 2005, 79, 137-143.	2.0	90
200	Intervención farmacológica en la fase prodrómica inicial de la psicosis. European Psychiatry (Ed) Tj ETQq0 0 0	rgBT/Ove	rlock 10 Tf 5
201	The European Prediction of Psychosis Study (EPOS): integrating early recognition and intervention in Europe. World Psychiatry, 2005, 4, 161-7.	10.4	108
202	Early detection and secondary prevention of psychosis: facts and visions*. European Archives of Psychiatry and Clinical Neuroscience, 2004, 254, 117-128.	3.2	183
203	Dimensions of working memory dysfunction in schizophrenia. Schizophrenia Research, 2003, 62, 259-268.	2.0	70
204	EPOS — General outlines of the "European prediction of psychosis study― Schizophrenia Research, 2003, 60, 5.	2.0	0
205	Early Detection and Intervention in the Initial Prodromal Phase of Schizophrenia. Pharmacopsychiatry, 2003, 36, 162-167.	3.3	122
206	A longitudinal multi-center fMRI study of cognition and emotion in first-episode schizophrenia patients. Pharmacopsychiatry, 2003, 36, .	3.3	0
207	Remembering or knowing: electrophysiological evidence for an episodic memory deficit in schizophrenia. Psychological Medicine, 2002, 32, 1261-1271.	4.5	83
208	381. Sensory gating: new vistas. Biological Psychiatry, 2000, 47, S116.	1.3	0
209	555. Early ERPS and their contribution to diagnosis in schizophrenia. Biological Psychiatry, 2000, 47, S169.	1.3	0
210	Effects of fluoxetine versus bright light in the treatment of seasonal affective disorder. Psychological Medicine, 1998, 28, 923-933.	4.5	77
211	Low Plasma Thyroid Indices of Depressed Patients are Attenuated by Antidepressant Drugs and Influence Treatment Outcome. Pharmacopsychiatry, 1996, 29, 180-186.	3.3	40
212	A Controlled Study of the Efficacy and Safety of Mianserin and Amitriptyline in Depressive Inpatients. Pharmacopsychiatry, 1995, 28, 249-252.	3.3	18
213	Clinical Response to Sleep Deprivation and Auditory-Evoked Potentials - Preliminary Results. Pharmacopsychiatry, 1994, 27, 70-71.	3.3	9
214	Evidence for a seasonal form of recurrent brief depression (RBD-seasonal). European Archives of Psychiatry and Clinical Neuroscience, 1994, 244, 205-210.	3.2	8
215	Application of transcranial magnetic stimulation in treatment of drug-resistant major depression-a report of two cases. Human Psychopharmacology, 1993, 8, 361-365.	1.5	191
216	Recurrent brief depression and its relationship to seasonal affective disorder. European Archives of Psychiatry and Clinical Neuroscience, 1992, 242, 20-26.	3.2	25

#	Article	IF	CITATIONS
217	Electroencephalographic Predictors of Psychosis. Key Issues in Mental Health, 0, , 133-141.	0.6	0